Celltrion has filed petitions for inter partes review of two patents related to Genentech’s trastuzumab: IPR2017-01121, challenging U.S. Patent 7,846,441, and IPR2017-01122, challenging U.S. Patent 7,892,549. According to the petitions, these two patents claim methods of treating patients with a sub-type of breast cancer with trastuzumab. These filings follow Celltrion’s earlier filing on a different trastuzumab patent, as we previously reported.
Trastuzumab is marketed by Genentech under the trade-name Herceptin®.
These petitions and other significant PTAB filings on biologic patents are collected on our IPR tracker page.